论文部分内容阅读
爱华活肝片的研制始于1972年,经十余年实验、临床、再实验、再临床的不断探索,终于形成了“爱华活肝片”系列(共22个品种)。1992年,该产品通过了著名的普林斯顿大学FDA标准实验室的毒性实验检测——1万倍剂量符合FDA要求。同年,该产品在美国华盛顿FDA总部正式备案,并在美国药厂生产,纽约肝病专科医院(纽约健康医院前身)销售。在投放市场以来的10年里,“爱华活肝片”以其可靠的疗效赢得了医药界的广泛赞誉。美国是一个医疗保险制度十分健全的国家,因此,除非患者对药物的疗效有十足的把握,否则他们是决不会自费取药的。“爱华活肝片”在美国销售的10年里,从未收取过任何形式的保险费,所有药费
The development of Epworth Huatuo Tablet began in 1972. After more than ten years of experiment, clinical trial, retesting and further clinical exploration, Epworth Huafeng Tablet has finally formed a series of 22 varieties. In 1992, the product passed the well-known toxicity test at the well-known Princeton University FDA Standards Laboratory - 10,000 times the dose meets FDA requirements. In the same year, the product was officially filed at the FDA headquarters in Washington, DC and was manufactured at a U.S. pharmaceutical factory and sold at the New York Liver Hospital (formerly New York Health Hospital). In the 10 years since it was put on the market, “Epworth Huagan Tablet” has won widespread praise from the pharmaceutical industry for its reliable curative effect. The United States is a country with a very healthy medical insurance system. Therefore, unless the patients are fully confident in the efficacy of the drugs, they will never take the medicine at their own expense. “Epworth live liver piece” in the United States for 10 years, never received any form of insurance, all the drugs